Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 594
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2151DJ-1ProteinHumanUpregulated in HCC DiagnosticNormal vs HCC with Hepatitis C and without Hepatitis C p < 0.05Urine23074380
2152CAF-1ProteinHumanUpregulated in HCC DiagnosticNormal vs HCC with Hepatitis C and without Hepatitis C p < 0.05Urine23074380
2153HSP60ProteinHumanUpregulated in HCC DiagnosticNormal vs HCC with Hepatitis C and without Hepatitis C p < 0.05Urine23074380
2154DJ-1, CAF-1ProteinHumanUpregulated in HCC DiagnosticNormal vs HCC with Hepatitis C and without Hepatitis C p < 0.05Urine23074380
2155DJ-1, HSP60ProteinHumanUpregulated in HCC DiagnosticNormal vs HCC with Hepatitis C and without Hepatitis C p < 0.05Urine23074380
2156CAF-1, HSP60ProteinHumanUpregulated in HCC DiagnosticNormal vs HCC with Hepatitis C and without Hepatitis C p < 0.05Urine23074380
2157DJ-1, CAF-1, HSP60ProteinHumanUpregulated in HCC DiagnosticNormal vs HCC with Hepatitis C and without Hepatitis C p < 0.05Urine23074380
2158hnRNP KProteinHumanUpregulated in HCC DiagnosticEarly HCC vs Late HCC p < 0.01Serum22760167
2159hnRNP K, AFPProteinHumanUpregulated in HCC DiagnosticEarly HCC vs Late HCC p < 0.01Serum22760167
2160miR-515-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2161miR-518a-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2162miR-520fmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2163miR-525-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2164Apo-A4ProteinHumanDownregulated in HCC patients DiagnosticHCC v/s other liver disease (cirrhosis/ALD) p < 0.01Plasma21160983
2165APO-A1ProteinHumanUpregulated in HCC patients DiagnosticHCC v/s other liver disease (cirrhosis/ALD) p < 0.01Plasma21160983
2166APO-A1, Apo-A4ProteinHumanAPO-A4 Upregulated and APO-A1 downregulated in HCC patients DiagnosticHCC v/s other liver disease (cirrhosis/ALD) p < 0.01Plasma21160983
2167CORO1CProteinHumanUpregulated in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis and higher coronin-1C expression had more advanced stage in patients PrognosticAgressive or advanced-stage HCC v/s less-aggressive HCC; predict metastatic stage p < 0.05Tissue and Cells 20181269
2168CYP1A1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2169CYP1B1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2170GDF15RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2171SERPINE1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2172SOS1RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2173RASD1RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2174MRASRNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2175NR1H4RNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2176PALMDRNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2177TXNIPRNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2178miR-122miRNAHumanvariable expression between different hepatoma cell lines: PLC/PRF/5, Huh-1, and Hep40 exhibited very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (e.g. SNU387, and SNU398) ; in HCC patients miR-122 was specifically repressed in Diagnostic and PrognosticNormal vs HCC; associated with survival, tumor size and differentiation status p < 0.001Tissue and Cells 19617899
2179lamin B1ProteinHumanUpregulated in liver cancer patients Diagnostic and PrognosticNormal vs HCC; significantly associated with the increased number of tumor nodules , the size of tumors, and tumor stage p < 0.01Plasma19522540
2180circCDK13circRNAsHumanSuppressed expression in liver cancer DiagnosticNormal cell line vs cancer cell line p < 0.05Tissue29658568
2181miR-101-3p, miR-106b-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2182miR-101-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2183miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2184miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2185miR-101-3p, miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2186miR-101-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2187miR-106b-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2188miR-101-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2189miR-101-3p, miR-106b-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2190miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2191miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2192miR-101-3p, miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2193miR-101-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2194miR-106b-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2195miR-101-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Serum29632649
2196miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Serum29632649
2197miR-101-3p, miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Serum29632649
2198miR-26amiRNAHuman cell lineDownregulated in HepG2 cells Potential Diagnostic *Normal cell line vs Liver cancer cell line p < 0.05Cells29430178
2199MTHFRRNAsHumanMTHFR polymorphism was associated with HCC occurrence PrognosticNormal vs HCC; predict recurrence in patients p < 0.05Tissue29185200
2200AFP, (with cut off 0.9 of AFP in serum )ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top